Arda’s $43 million Series A to progress cell depletion therapies

California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round.

Arda is looking to change a paradigm within drug development. The dominant approach for decades has been to modulate individual proteins and signaling pathways to ameliorate disease. 

While this strategy has yielded some success, it often leads to limited efficacy and incremental gains, particularly for complex chronic diseases.